Furthermore, a molecule targeting the mutated p53, named PRIMA-1MET, combined with carboplatin chemotherapy is used in the II phase of clinical trials of recurrent high-grade serous ovarian cancer (NCT02098343). Here, TP53 is linked to ovarian serous adenocarcinoma.